Key Highlights

  • Intellia Therapeutics was in focus after Barclays initiated coverage with an Underweight rating, an unusually cautious first call.
  • The company develops therapies based on CRISPR gene editing, including treatments designed to be given once to edit genes inside the body.
  • The initiation landed during a weak session for health care, the only S&P 500 sector to decline that day.
  • Fellow CRISPR developer Caribou Biosciences plunged in after-hours trading the same day, also with no announcement found.

Intellia Therapeutics (NASDAQ:NTLA) was in focus on Tuesday, October 6, after Barclays initiated coverage with an Underweight rating. That rating signals that the bank expects the shares to lag the group it measures them against. Launching coverage with a negative stance is less common than starting with a neutral or positive view, which is one reason the call drew notice. The size of Intellia's move on the day was not captured in the reports reviewed.

The detailed reasoning and any price target behind the Barclays initiation were not available in the sources reviewed. Assessments of gene-editing companies often turn on the timing and probability of clinical and regulatory milestones, the size of potential markets and the cash needed to reach commercialization.

Intellia is a biotechnology company developing therapies based on CRISPR gene editing, including treatments designed to be given once to edit genes inside the body. Like many of its peers, it depends on Capital Markets and partners to fund research.

Health Care Was the Day's Only Loser

The initiation landed during a weak session for the sector. Health care was the only one of the 11 major S&P 500 sectors to finish lower, and small caps suffered most. Only 48 of the 428 health-care members of the Russell 2000 advanced on the day.

Other biotech and diagnostics names slid as well. ArriVent BioPharma (NASDAQ:AVBP) tumbled with no catalyst found, OmniAb (NASDAQ:OABI) and CG Oncology (NASDAQ:CGON) fell, and Vaccine makers Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) retreated after the World Health Organization rated the risk from a pneumonic plague outbreak as low. After the close, fellow CRISPR developer Caribou Biosciences (NASDAQ:CRBU) plunged in extended trading, with no company announcement found to explain the move.

Not every analyst action in the space was negative. Cantor Fitzgerald upgraded Rezolute (NASDAQ:RZLT) to Overweight, and Guggenheim assumed coverage of several neuroscience-focused biotech names at Buy.

Small Caps Trail Record Highs

The wider market had a strong day at the top. The S&P 500 climbed about 45 points to a record 7,818.93 and the Nasdaq Composite closed at a record just under 27,600, driven by technology and a surge in utilities after Constellation Energy's (NASDAQ:CEG) 20-year nuclear power agreement with Google (NASDAQ:GOOGL). The Russell 2000, by contrast, slipped about 17 points to roughly 2,830.

Breadth was weaker than the headline numbers suggested. On the Nasdaq, 1,925 stocks fell while 1,463 rose, even as the composite set a high.

Rates Still Set the Tone

Treasury yields eased on Tuesday, with the 10-year near 5.28, but remain close to the highest levels since 2002. For companies like Intellia, whose potential profits lie years ahead, higher rates reduce the present value of those future Earnings and can make raising money more costly.

Other Brokers' Reactions Will Be Telling

Investors will be looking for any detail from Barclays on its assumptions and for whether other Brokers revisit their views on Intellia. Company updates on clinical programs will remain the biggest driver.